PREVALENCE OF GASTRIC PRECANCEROUS CONDITIONS : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/7yggg895Keywords:
Gastric Precancerous, Prevalence, IncidenceAbstract
Background: Gastric carcinoma is a common malignant disease associated with an unfavorable prognosis in the case of late dia-gnosis. The most significant precancerous condition is chronic atrophic gastritis and intestinal metaplasia caused by Helicobacter pylori infection. These longlasting changes may lead to formation of dysplastic precancerous lesions.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 1.045 articles, whereas the results of our search on SagePub brought up 701 articles. The results of the search conducted for the last year of 2013 yielded a total 12 articles for PubMed and 8 articles for SagePub. In the end, we compiled a total of 4 papers, 3 of which came from PubMed and 1 of which came from SagePub. We included five research that met the criteria.
Conclusion: Precancerous conditions including chronic atrophic gastritis gastritis, metaplasia, foveolar hyperplasia and gastric hyperplastic polyps derived from the gastric epithelium have been concluded, based on the overview of gastric epithelial histological organization and its renewal.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
Poorolajal J, Moradi L, Mohammadi Y, Cheraghi Z, Gohari-Ensaf F. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiol Health. 2020;
Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clin Gastroenterol Hepatol
Lagergen J, Andersson G, Talback M, Drefahl S, Bihagen E, Harkonen J, et al. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site. Cancer. 2016;122(2):207–12.
Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh Kh. Management of gastric cancer in Asia: resource-stratified guidelines. Lance Oncol. 2013;14(12):535–47.
Pimentel-Nunes P, Libanio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–88.
Gupta S, Li D, Serag HBE, Davitkov P, Altayar O, Sultan S, et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology. 2020;158(3):693–702.
Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel). 2021;11(8):1305.
Beresniak A, Malfertheiner P, Franceschi F, Liebaert F, Salhi H, Gisbert JP. Helicobacter pylori Test-and-Treat strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. Helicobacter. 2020;25(4).
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
Mera RM, Bravo Le, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut
Xiao HF, Yan SP, Chen YF, Shi Z, Zou YH, Zhu SL, et al. Community-Based Upper Gastrointestinal Cancer Screening in a Randomized Controlled Trial: Baseline Results in a Non-high-incidence Area. Randomized Controlled Trial
Esmaeilzadeh A, Goshayeshi L, Bergquist R, Jarahi L, Khooei A, Fazeli A, et al. Characteristics of gastric precancerous conditions and Helicobacter pylori infection among dyspeptic patients in north-eastern Iran: is endoscopic biopsy and histopathological assessment necessary BMC Cancer. 2021 Dec 1;21(1).
Song H, Ekheden IG, Zheng Z, Ericsson J, Nyren O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ
Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. Pathobiology. 2018;85(1–2):50–63.
Hackeng WM, Montgomery EA, Giardiello FM, Singhi AD, Debeljak M, Eshleman JR, et al. Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology. 2017;70(4):549–57.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
